Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

Also called NCT03088670

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 299 participants (enrolled count) (from the registry)
Sponsor
SatRx LLC (from the registry)
Registry
  • NCT NCT03088670
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03088670. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2014-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Gosogliptin
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Metformin
Lead sponsor
SatRx LLC (class: industry)

Record details

Record id
cardio:ct-nct03088670
Content hash
f77671f83cc202863e5d9c8fffa5e8ae7f659505d8928cc1417dd599a1cbd623